Marek Mraz research group

Joined January 2020
Are there other antibodies, besides rituximab/obinutuzumab, that should be tested in combination with BTK inhibitors in CLL? We think that anti-CXCR4 antibodies are particularly interesting candidates (Pavlasova et al, HemaSphere): onlinelibrary.wiley.com/doi/…
1
1
83
The IMF mourns the passing of Dr. Robert A. Kyle, the “Father of Myeloma.” His life’s work helped transform myeloma research, treatment, and care, and his influence will continue for generations. Read more: mmsm.link/3Tf64JB
1
38
3
92
4,423
Replying to @DanaFarber
@DanaFarber’s Cathy Wu, a pioneer in personalized cancer vaccines, spoke with the @nytimes about historic news from @Moderna that a vaccine slowed the return of melanoma and its spread to other parts of the body nytimes.com/2026/08/19/scien…
9
31
2,276
Replying to @ENCODE_NIH
@ENCODE_NIH GRAMMAR is now on the UCSC Genome Browser! 🧬 Base-resolution deep learning predictions, sequence contribution scores & motif instances (BPNet, ChromBPNet, ProCapNet, ReporterNet) across thousands of ENCODE experiments. Explore on hg38: genome.ucsc.edu/s/Lou/ENCODE…
1
37
3
123
16,285
The wait ⏰ is over! Most structure prediction tools give you 1 answer. #RNA just doesn’t work that way - it's the ultimate shapeshifter. Today, we’re launching #RNAccess by Emergente Inc. with access for academic, nonprofit, and commercial researchers. RNAccess is powered by #RNAnneal, our physics-grounded #AI engine for #RNA structure prediction. By combining physics-based simulation with Generative AI, RNAnneal captures the structural flexibility that makes RNA both incredibly challenging—and incredibly powerful. The workflow is simple: 🧬Submit an RNA sequence of up to 100 nucleotides (long RNAs coming soon). ⚡Receive a thermodynamically ranked ensemble of high-accuracy 3D structures. 🔍Explore results through intuitive, interactive visualizations in your browser. 🦠Example: A key functional region of SARS-CoV-2 #RNA pictured below was predicted + visualized accurately in #RNAccess (with no prior knowledge, just physics!) We built #RNAccess to make serious RNA structure prediction more accurate, accessible, and useful for researchers working across all RNA work, from fundamental discovery to applied innovations. No local compute. No pipeline setup. No coding experience needed. Not even a GPU bill - we’ve got that covered 🙇 🎓Academic/non-commercial researchers: Receive a free batch of predictions every month, with pay-as-you-go options when you need more. 🏢Commercial teams: Start with a complimentary prediction, then talk with us about evaluation, confidential use, and larger-scale applications. 📍Try RNAccess: emergente-sci.com 📍Contact: [email protected] Come fold with us 💫 ------------------ It took a village to get this far. Thank you to @NIH-NIGMS, @NSF -Chemistry-CTMC, TEDCO, University of Maryland Institute for Health Computing, Institute for Physical Science and Technology, Montgomery County Government, UMD Chemistry and Biochemistry, @UMDscience, @UMmedschool and many others for financial and other support. Gratitude to leadership Bradley Maron, MD, Adam Porter, @VarshneyAmitabh, Mark T. Gladwin, MD, Martha Jurczak for their continued faith in our team at University of Maryland Institute for Health Computing and in Emergente Inc. - the first startup out of the IHC! And finally, huge thanks to our awesome scientific advisers Robert Copeland, Jonathan Dinman and John (Jay) Schneekloth for their guidance.
9
70
2
331
22,286
How to link a non-coding disease GWAS variant to its target genes in the right cell type? ENCODE-rE2G, now out in @Nature addresses this through optimal integration of chromatin activity and 3D contact data in 1,458 biosamples. A huge collaborative effort spanning 6+ years led by @argschwind @jengreitz nature.com/articles/s41586-0…
1
26
91
7,054
A fantastic EHA 2026 for the lab: 3 oral presentations, 2 posters, many inspiring discussions, new collaborations taking shape, and, as always, the opportunity to reconnect with friends and colleagues.
5
105
Pretty interesting story in @ScienceMagazine this week on what looks like a serious problem in the senescence field. More than 400 papers apparently used the wrong antibody for p16-INK4a — an antibody that actually recognizes a completely different, unrelated protein (a component of the actin cytoskeleton). This affects work on senescent cell accumulation in aging and disease, and most critically, some of the evidence base for senolytic drug research. What concerns me most is that many of these papers somehow got the "right" answer using the wrong antibody. That's not just an innocent reagent mix-up — it raises real questions about data fabrication or selective reporting in at least some of these labs. I've commented before about how ignoring data that doesn't fit the narrative is a major problem in certain areas of the longevity literature (e.g. sirtuins and NAD), and here a potentially widespread example in senescence. Hopefully journals will investigate and retract as necessary, but based on my experience that seems optimistic. One concrete fix is that journals should flag problematic antibody product codes at submission so reviewers can catch this before publication. Reviewers should absolutely be on the lookout for this going forward. However, these fixes won't address the larger problem. We need to understand how these scientists got the results they wanted and published them over 400 times (!!!): whether through intentional deception, incompetence, accident, or some legitimate explanation. Credit for discovering this goes to @addictedtoigno1 who wrote about it first on his blog: For Better Science science.org/content/article/…?
22
94
23
369
101,295
Excited to share the first pre-print from our lab!! Check it out here! biorxiv.org/content/10.64898… We found that many RNA-binding proteins understood to regulate RNA processing can also function like transcription factors and cofactors to directly regulate transcription.
4
84
340
21,065
Late breaking from #ASCO26 Day 2 for Lymphoma- FrontMIND trial 👉 Tafa+ Len + RCHOP vs RCHOP in 1L DLBCL IPI 3-5 👉 HR for PFS 0.75 👉 2 yr median PFS 72% vs 65% 👉 overall rate G3/4 TEAEs comparable, but increased cytopenias; febrile neutropenia in Tafa/Len/RCHOP ⭐️Potential new SOC option for 1L DLBCL in high risk pts, regardless of COO. My concerns : Difficult regimen with weekly Tafa and 10 days of Len; higher myelosuppression/VTE risk with Len; plus concern of CD19 loss and efficacy of 2L CAR 🚗
2
7
2
27
6,269
Amazing! I’m impressed both with the results for a disease we have struggled against forever: pancreatic cancer; and the fact that we can target what we thought we could not ever: RAS. #ASCO26 @NEJM nejm.org/doi/full/10.1056/NE…
4
20
2
157
9,721
Dr. Daniel Filip (Dano) has completed his PhD. Very proud of him and the work he has done in the lab (Filip et al, Leukemia, 2026 + 5 other papers). We have a new doctor !
16
743
Just out: Majestic Majestec-9 results. #ASCO26 @NEJM Single agent teclistamab beats standard triplet in relapsed myeloma. nejm.org/doi/full/10.1056/NE… @DrOlaLandgren @thanosdimop
6
52
5
174
21,324
Very humbled and honored to receive the Jessenius Award (Physician of the Year 2025) from the Patients Association of the Czech Republic. Named after Jan Jessenius,who performed the first public autopsy in the Czech lands (1600) and wrote an important book on surgical procedures.
3
9
493
38th Olomouc hematology days are coming to its end, ~900 participants from 🇨🇿🇺🇸🇱🇹🇸🇪🇸🇰. Friendship, science and education! Thanks for TOP talks by @MrazLab @GregNowakowski @Dr_Daniel_Molin @prokop_whaaat @Danielakov2 @JamieFlerlage @MarekTrnenyDr team K Polgarova a P Klener! 🤝
1
3
1
12
623
Great evening with Greg Nowakowski, thank you for coming to Olomouc Hematology Days !
Wiedermann lecture award goes to @GregNowakowski this year! Olomouc hematology days 🇨🇿 have started big! Congratulations!
1
6
1,727
ERC is doing some strange thing
Announced by the ERC today (really bad news for science!!! It starts in Europe but will affect everybody) Because the REVIEWING LOAD is so bad, if your application fails you may need to wait mulitple years (>3?!?) until you can submit again! The ERC is the lifeline of the leading labs in Europe, so many research programs will be terminated (just no other sources to compensate). The letter from the ERC says “the only way is to reduce applications” (highlighted in the picture below) No!!! It's the wrong direction. Use AI to assist review. It’s not perfect (yet), but it allows more proposals to be evaluated, and it could support, not replace, human reviewers.
1
5
235
Moje laborka hledá lab manažera/ku - znalost češtiny je nutná
2
4
1,029